Study finds bupropion SR effective in treating neuropathic pain

November 12, 2001

ST. PAUL, MN -- Patients with neuropathic pain found greater relief, and fewer side effects, when treated with bupropion SR (sustained-release) than with commonly prescribed treatments. These findings came from a study conducted at the University of Arizona Neurology Clinic and Pain Clinic in Tucson, and published in the November 13 issue of Neurology.

"The results of our placebo-controlled study support previous preliminary data that bupropion SR, at a dosage of 150 to 300 mg/day, may be clinically effective for the treatment of neuropathic pain," according to study author Marilyn Semenchuk, PharmD, Dept. of Neurology at the University of Arizona at Tucson. Approximately three-quarters of the patients treated in the trial reported that their pain was improved by an average of 30 percent with bupropion SR.

Neuropathic pain, which results from a disturbance of the peripheral or central nervous system, includes symptoms such as shooting and burning sensations, numbness, and tingling. Neuropathic pain has commonly been treated with tricyclic antidepressants (TCAs). But many patients stop taking these drugs because they may not effectively reduce the pain, or because the drugs leave them with intolerable side effects. Bupropion SR is a second generation non-TCA.

The forty-one patients who participated in the study were all clinically diagnosed with neuropathic pain, were screened to determine the absence of depression, and were medically stable. Semenchuk said the researchers limited the study to nondepressed patients since there is a belief that patients with chronic pain may also be depressed and the reason the antidepressant medications work for treating neuropathic pain is not as an analgesic but by alleviating the depression. The argument has been that once the depression is alleviated, the pain is better. "By using nondepressed patients, the previous argument doesn't hold," said Semenchuk .

The 12-week outpatient study compared bupropion SR 150 mg with an inactive placebo. Neither the patient nor the doctor knew whether the patient was taking the bupropion or the placebo. Half the patients were on the placebo for the first six weeks, and the medication for the second six weeks. The other half received the medication first.

Seventy-three percent, or 30 of the patients reported their pain was improved or much improved after six weeks of bupropion therapy, whereas 90 percent claimed their pain became worse or remained unchanged while receiving the placebo. Semenchuk recommended additional larger scale studies to confirm the results.
-end-
The study was supported, in part, by a grant from Glaxowellcome, a division of GlaxoSmithKline.

The American Academy of Neurology, an association of more than 17,700 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. For more information about the American Academy of Neurology, visit its web site at www.aan.com.

For more information contact:
Kathy Stone, 651-695-2763; kstone@aan.com
For a copy of the study, contact Cheryl Alementi, 651-695-2737; calementi@aan.com

American Academy of Neurology

Related Depression Articles from Brightsurf:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.

Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.

Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.

Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.

A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.

Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.

Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.

Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.

Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.

CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.

Read More: Depression News and Depression Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.